Daily treatment with JT002 at 30 mg/kg administered by oral gavage to mice expressing the Nlrp3 A350V mutation resulted in the attenuation of inflammation and hepatic fibrosis compared to vehicle control mice and maintained total white blood cell counts and ALT levels within normal ranges. The gene discussed is NLRP3; the disease is Hepatic fibrosis.